UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2025

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 19, 2025, AC Immune SA ("**AC Immune**") held its Annual General Meeting of Shareholders. The final results of the voting on the agenda items are given below. The Management presentation to shareholders is attached hereto as Exhibit 99.1. Prior to the meeting, the board of directors of AC Immune withdrew agenda items 6.1 and 6.2. The final results of the remaining agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune's website (https://ir.acimmune.com/governance) within 15 days:

Annual General Meeting Results

Agenda Item 1: 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements, 2024 Compensation Report

Agenda Item 1.1: Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory Financial Statements

AC Immune shareholders approved the 2024 IFRS Consolidated Financial Statements and the 2024 Statutory Financial Statements.

Agenda Item 1.2: Advisory Vote on the 2024 Compensation Report

AC Immune shareholders endorsed the 2024 Compensation Report.

Agenda Item 2: Appropriation of Losses

AC Immune shareholders approved that the net loss for the year 2024 in the amount of CHF 45,848K increases the "accumulated losses brought forward" of CHF 310,998K, resulting in a new balance of "accumulated losses brought forward" of CHF 356,846K.

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Committee

AC Immune shareholders approved the discharge of the Members of the Board of Directors and the Executive Committee for the financial year 2024.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2025 to the AGM 2026

AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 1,029K (excluding employer social security contributions) covering the period from the AGM 2025 to the AGM 2026.

Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2026

AC Immune shareholders approved the total maximum compensation for the members of the Executive Committee of CHF 7,496K (excluding employer social security contributions) from 1 January 2026 to 31 December 2026.

Agenda Item 5: Re-elections and Elections

Agenda Item 5.1: Re-elections of Members of the Board of Directors

AC Immune shareholders approved the re-election of Monika Bütler, Carl June, Andrea Pfeifer, and Roy Twyman as Members of the Board of Directors, each until the end of the Annual General Meeting 2026.

Agenda Item 5.2: Elections of Members and Chair of the Board of Directors

AC Immune shareholders approved the election of Renée Aguiar-Lucander as Member of the Board and of Martin Zügel as Member and Chair of the Board.

Agenda Item 5.3: Re-election of Members of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the re-election of Monika Bütler and Roy Twyman as Members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2026.

Agenda Item 5.4: Election of Member of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the election of Martin Zügel as Member of the Compensation, Nomination and Corporate Governance Committee until the end of the Annual General Meeting 2026.

Agenda Item 5.5: Re-election of the Statutory Auditors

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Lausanne, Switzerland, as AC Immune's statutory auditors for the financial year 2025.

Agenda Item 5.6: Re-election of the Independent Proxy

AC Immune shareholders approved the re-election of Reymond & Associés Attorneys, Lausanne, as AC Immune's Independent proxy until the end of the Annual General Meeting 2026.

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By: /s/ Andrea Pfeifer
Name: Andrea Pfeifer
Title: Chief Executive Officer

By: /s/ Christopher Roberts
Name: Christopher Roberts
Title: Chief Financial Officer

Date: June 20, 2025

EXHIBIT INDEX

Exhibit Number	Description
99.1	Annual General Meeting Presentation

Exhibit 99.1

Investor Update

NASDAQ: ACIU | Annual General Meeting – June 19, 2025

AC Immune

Disclaimer

This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CH, CN, EU, GB, JP, KR, NO and RU.

Agenda

1. AC Immune's approach to neurodegenerative diseases
2. Achievements 2024
3. Business strategy and pipeline update
4. Clinical-stage active immunotherapy programs
5. Programs targeting a-syn and NLRP3 inflammasome
6. Key milestones 2025
7. Financial figures
8. Summary and Strategic outlook
9. Agenda items and proposals of the Board of Directors

1. AC Immune’s approach to neurodegenerative diseases



AC Immune today – an overview

Pioneering next generation Precision Medicine for neurodegenerative diseases

Diverse and balanced pipeline with a large number of wholly-owned assets

Key differentiation: Precision Medicine
Enabled by leadership in Active Immunotherapy

New breakthroughs, e.g. morADC[3]: our platforms have repeatedly created potentially transformative innovations

Partnering: strategic, risk-mitigating, timely, monetization with >CHF 4 billion in potential milestones

Cash reserves on Balance sheet
Funding into Q1 2027

- Based in Lausanne, Switzerland
- ~170 employees
- Listed September 2016 (NASDAQ: ACIU)
- 100.6 million shares outstanding[1]
- Cash resources of CHF 145.7 million[2]

(1) As of March 31, 2025; excluding treasury shares; (2) As of March 31, 2025; (3) Morphomer-antibody drug conjugate

Neurodegenerative diseases

Prevention as the best approach to long-term preservation of neurological health

Global Prevalence of AD[1] Stages[2] (million)



Diagnostics enable earlier intervention

Active immunotherapy for treatment and prevention

Co-pathologies in NDD[4]



- AD prevention through combination of advanced diagnosis and early active immunotherapy
- Global disease prevention market potentially over 300 million people

(1) Alzheimer's disease; (2) Gustavsson et al. Alzheimer's and Dement. 2023 19:658-670. https://doi.org/10.1002/alz.12694; (3) Monoclonal antibody; (4) Neurodegenerative disease; (5) alpha-synuclein; (6) TAR DNA-binding protein 43; (7) Amyotrophic lateral sclerosis; (8) Limbic-predominant age-related TDP-43 encephalopathy

2. Achievements 2024



AC Immune 2024 highlights

The foundation for early detection and treatment

Clinical-stage active immunotherapies

Targeted active immunotherapies:

- **ACI-24.060**[1] (Takeda)
  Exclusive option and license agreement
- **ACI-35.030**[2] (Janssen J&J)
  Phase 2b trial program, ReTain
- **ACI-7104.056**[3] (wholly-owned)
  Phase 2 trial, VacSYn
  positive interim safety and immunogenicity

Pipeline and technologies

Biologics, small molecules, combo's

- Wholly-owned assets advanced towards clinical development
- morADC platform unveiled at AAIC with preclinical a-syn[4]/a-syn results
- Small molecule programs targeting a-syn, Tau and NLRP3[5] reaching value inflection points
- Clinical entry of a-syn and TDP-43[6] PET[7] tracers

Strong financial position

Operating capital foundation:

- Partner payments in 2024:
  - **ACI-24.060** (Takeda)
    $100 million upfront payment
  - **ACI-35.030** (Janssen J&J)
    CHF25 million milestone payment
- Cash runway into 2027

Cash runway permits achievement of key milestones & execution of value-generating innovation

(1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha-synuclein; (5) (NOD)-like receptor protein 3; (6) TAR DNA-binding protein 43; (7) Positron emission tomography

3. Business strategy and pipeline update



AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations

ACI-35.030 anti-pTau

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

ACI-24.060 anti-Abeta

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

a-syn-targeted programs for PD

A unique suite of disease-modifying therapeutics and diagnostics targeting pathological a-syn

NLRP3 inflammasome

Inhibiting neuroinflammation to alleviate disease pathology and disrupt the negative feedback loop

Broad and robust pipeline in neurodegenerative diseases

Driven by validated proprietary technology platforms for sustained growth



(1) alpha-synuclein; (2) (NOD)-like receptor protein 3; (3) Apoptosis-associated speck-like protein containing a CARD, also PYCARD; (4) Amyotrophic lateral sclerosis; (5) TAR DNA-binding protein 43; (6) Neurodegenerative diseases; (7) Alzheimer's disease; (8) Down syndrome

Precision medicine approach enabled by the Morphomer® platform

Developing a suite of tracers against emerging targets in neurodegenerative diseases

	Indication	Candidate	Partner	Modality	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Wholly-owned	Parkinson's disease	ACI-15916		*a-syn[1]-PET[2] tracer (diagnostic)*					
	MSA[3]	ACI-12589		*a-syn-PET tracer (diagnostic)*					
	ALS[4]	ACI-19626		*TDP-43 [5]-PET tracer (diagnostic)*					
Partnered	Alzheimer's disease	PI-2620	Life Molecular Imaging	*Tau-PET tracer (diagnostic)*				FDA Fast Track	



(1) alpha-synuclein; (2) Positron emission tomography; (3) Multiple system atrophy; (4) Amyotrophic lateral sclerosis; (5) TAR DNA-binding protein 43

Technology platforms driving value-creating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform		
Wholly-owned Programs	■ a-syn active immunotherapy ■ Anti-TDP-43 mAb[1] ■ Anti-NLRP3-ASC mAb	■ morADC	■ Mor-a-syn ■ Mor-TDP-43 PET / Mor-a-syn PET ■ Mor-NLRP3-ASC

- Over CHF 400 million in upfront payments from deals; further >CHF 4.3 billion possible
- Considerable additional potential value in our unpartnered clinical and preclinical programs

(1) Monoclonal antibody

4. Clinical-stage active immunotherapy programs

ACTIVE Immune Therapy



Active immunotherapies driving Precision Prevention

Three clinical-stage programs supported by promising data from prior trials

Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Status
ACI-24.060 *(anti-Abeta)*	AD[1] treatment			FDA Fast Track		Phase 1b/2 **ABATE** trial ongoing
	AD treatment (*Down syndrome*[2])					
ACI-35.030 / JNJ-2056 *(anti-pTau)*	AD therapy			FDA Fast Track		Phase 2b **ReTain** trial ongoing
ACI-7104.056 *(anti-a-syn*[3]*)*	PD[4], a-synucleinopathies					Phase 2 **VacSYn** trial ongoing

(1) Alzheimer's disease; (2) Down syndrome-related Alzheimer's disease; (3) alpha-synuclein; (4) Parkinson's disease

ACTIVE Immune Therapy

targeting neurodegenerative diseases

Major advantages

- Long-lasting specific immunity for pathological target, consistent, boostable
- Limited annual dosing (once or twice) after priming year
- No observed ARIA-E[1] to date (safety profile well suited to long-term use)
- Ease of administration and simple logistics for global access
- Cost-effective (attractive healthcare economics across global populations)



Active immunotherapy

Stimulates the patient's immune system to produce their own antibodies

Passive immunotherapy

Externally generated mAb requires administration every two to four weeks



(1) Amyloid-related imaging abnormalities-edema

Active immunotherapy: a new class of treatment for neurodegenerative disease

Potential for profound social and economic impact



ACTIVE Immune Therapy for global treatment and prevention of neurodegenerative diseases

5. Programs targeting a-syn and NLRP3 inflammasome



AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations

ACI-35.030 anti-pTau

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

ACI-24.060 anti-Abeta

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

a-syn-targeted programs for PD

A unique suite of disease-modifying therapeutics and diagnostics targeting pathological a-syn

NLRP3 inflammasome

Inhibiting neuroinflammation to alleviate disease pathology and disrupt the negative feedback loop

Pioneering a-syn[1] modalities to address Parkinson's disease

Unique pipeline assets: 3 therapeutics and 2 diagnostics

- **Active immunotherapy** targeting pathological oligomeric a-syn to prevent spreading and neurodegeneration
- In **Phase 2 trial** in early PD[2] with safety and immunogenicity data reported in H2 2024

ACI-7104.056

Mor-a-syn

- **Small molecule Morphomer®** targets intracellular pathological a-syn aggregates to treat and prevent Parkinson's disease
- **Lead candidate decision** anticipated in 2025

- **Small molecule Morphomer® ADC**[3] with enhanced **brain penetration** and **potency** compared to either parent molecule
- **New Platform technology**: Lead discovery

morADC

ACI-12589
ACI-15916

- **Morphomer® diagnostic PET**[4] **tracers** for pathological a-syn aggregates to detect and differentiate a-synucleinopathies
- Excellent selectivity with **IND**[5]**-enabling studies**[6] completed in H2 2024

- Parkinson's disease affects over 6 million people worldwide
- Challenges remain in diagnosis and there are substantial unmet needs for effective therapeutic interventions

(1) alpha-synuclein; (2) Parkinson's disease; (3) Antibody drug conjugate; (4) Positron emission tomography; (5) Investigational New Drug; (6) IND-enabling studies for ACI-15916

AC Immune's four core value-driving pillars

Combining biomarker-based clinical development, validated targets and strong collaborations

ACI-35.030 anti-pTau

The only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease

ACI-24.060 anti-Abeta

Biomarker-driven development targeting the hallmark protein in Alzheimer's disease and Alzheimer's in Down syndrome

a-syn-targeted programs for PD

A unique suite of disease-modifying therapeutics and diagnostics targeting pathological a-syn

NLRP3 inflammasome

Inhibiting neuroinflammation to alleviate disease pathology and disrupt the negative feedback loop

NLRP3[1] Inflammasome is a promising therapeutic target

Key disease driver in multiple CNS and other diseases



AC Immune's unique positioning

- Potential best-in-class compounds
  - Small molecule therapeutics
  - Monoclonal antibody diagnostics
- Multiple substantial indications

CNS[10]
- Parkinson's disease
- Alzheimer's disease
- Multiple sclerosis
- Other NDDs[11]

Other
- Obesity
- Type 2 diabetes
- Rheumatoid arthritis
- IBD[12]

- Mechanism of action can be applied across a broad range of neuroinflammatory and other diseases
- Pharmacological inhibition of NLRP3 lowers aberrant cytokine release and reduces disease pathology [13,14,15]

(1) Nod-Like Receptor protein containing Pyrin 3; (2) Apoptosis-associated speck-like protein containing a CARD, also called PYCARD; (3) monoclonal antibody; (4) TAR DNA binding protein-43; (5) Venegas *et al.*, 2017; (6) phosphorylated Tau; (7) alpha-synuclein; (8) Interleukin-1 beta; (9) Interleukin-18; (10) Central nervous system; (11) neurodegenerative diseases; (12) Inflammatory bowel disease; (13) Stancu *et al.*, 2019; (14) Dempsey *et al.*, 2018; (15) Gordon *et al.*, 2018

6. Key milestones 2025



Key milestones

Multiple catalysts across pipeline including selected 2025 milestones

● Readouts
○ Other development events

Active immunotherapies		H1'25	H2'25	
ACI-24.060 (Takeda)	Abeta		●	**ABATE Phase 2 trial 12-month treatment completed in AD[1] Dec. 2025**
ACI-7104.056	a-syn[2]	●		**Phase 2 VacSYn trial in PD[3]: Part 1 interim results, pharmacodynamics, biomarkers**
			○	Phase 2 VacSYn trial in PD: Part 2 Initiation[4]
Monoclonal antibodies and small molecule drugs				
Monoclonal antibody	TDP-43[5]		○	Validated pharmacodynamic assay for clinical readout
Morphomer-NLRP3 (ACI-19764)	NLRP3[5]	✓		**Lead candidate declaration** and initiation of IND-enabling studies
			○	IND[7]/CTA[8] filing
Morphomer-Tau	Tau		●	**Lead candidate declaration** and initiation of IND-enabling studies
Morphomer a-syn	a-syn		●	**Lead candidate declaration**
morADC	Platform (a-syn)	✓		***In vivo*** **PoC study** of proprietary brain delivery platform
Diagnostics				
TDP-43-PET[9] tracer	TDP-43		●	**Phase 1 initial readout in genetic FTD[10]**
a-syn-PET tracer (ACI-15916)	a-syn		●	**Phase 1 readout**

(1) Alzheimer's disease; (2) alpha-synuclein; (3) Parkinson's disease; (4) IND/CTA approval; (5) TAR DNA-binding protein 43; (6) (NOD)-like receptor protein; (7) Investigational new drug; (8) Clinical Trial Application; (9) Positron emission tomography; (10) Frontotemporal dementia

7. Financial figures



2024 Financial Overview

Key financial data (IFRS)

For the year ended December 31,	2024	2023	Change (in CHF million) (except per share data)
Revenues	27.3	14.8	12.5
R&D expenses	(62.6)	(54.6)	(8.0)
G&A expenses	(17.3)	(15.3)	(2.0)
Other operating income	0.1	1.5	(1.4)
Total Operating expenses	**79.8**	**68.4**	**(11.4)**
Finance result, net	1.5	(0.6)	2.1
IFRS loss for the period	**(51.0)**	**(54.2)**	**3.2**
IFRS EPS – basic and diluted	(0.51)	(0.64)	0.13

As of December 31,	2024	2023	Change (in CHF million)
Cash and cash equivalents	36.3	78.5	(42.2)
Short-term financial assets	129.2	24.6	104.6
Total liquidity[1]	**165.5**	**103.0**	**(62.5)**
Total shareholder's equity	112.3	160.6	(48.3)

(1) Liquidity is defined as the cash and cash equivalents plus short-term financial assets. These short-term financial assets are cash held in fixed-term deposits ranging in maturity from 3–12 months

AC Immune strong Balance Sheet

Operations well-funded into 2027

Cash of **CHF 145.7 million**[1]

2025 annual cash burn guidance
CHF 75m – 85m

Strong Balance Sheet[2]
Cash runway into Q1 2027

Astute investment strategy focused on major value drivers and near-term catalysts

(1) As of March 31, 2025; (2) Assumes no other milestones or deals included

AC Immune strong track record in deals[1] with leading pharma companies

Strategy: optimize value to risk ratio and retain significant upside

Program	Phase	Total value[2]	Upfront[2]	Milestones received[2]	Royalties %	Partner
ACI-24.060 (anti-Abeta active immunotherapy)	Phase 1b/2	>USD 2,100	USD 100		Mid-to-high teens	Takeda
ACI-35.030 (anti-pTau active immunotherapy)	Phase 2b	CHF 500	CHF 26	CHF 20	Low-double digits to mid-teens	Janssen
Tau Morphomer® (small molecule drugs)	Phase 1 [6]	CHF 1,860	CHF 80 +USD 50 [7]	CHF 40	Low-double digits to mid-teens	Lilly
PI-2620 (Tau PET[4] tracer)	Phase 3 [5]	EUR 160	EUR 0.5	EUR 7	Mid-single digits to low-teens	Life Molecular Imaging
Other (concluded collaborations)		CHF 121 [3]	CHF 41	CHF 80		
Total (millions)[8]		**CHF ~4,750**	**CHF 255.2 [9]**	**CHF 147.4**		

- Outstanding potential milestone payments exceed ~CHF 4.3 billion

(1) Disclosure limited due to confidentiality agreements with collaboration partners; (2) In millions; (3) Total payments received from partner until conclusion of agreement; (4) Positron emission tomography; (5) In Alzheimer's disease; (6) Phase 1 completed; (7) Equity investment; (8) Converted to CHF on date of receipt; (9) Excludes convertible note agreement of USD 50 million

AC Immune technology platforms driving validating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform				
Program	ACI-24.060	ACI-35.030	Mor Tau	Tau PET
Partner	Takeda	janssen	Lilly	Life Molecular Imaging

- An integrated approach to Central Nervous System (CNS)-specific therapies

8. Summary and Strategic outlook



Creating the future of Precision Medicine in neurodegeneration

The foundation for early detection and treatment

ACTIVE Immune Therapy

Advance clinical-stage active immunotherapies

Targeted active immunotherapies:

- **ACI-24.060** Phase 1b/2 (with Takeda)[1]
- **ACI-35.030** Phase 2b (with Janssen J&J)[2]
- **ACI-7105.056** Phase 2 (wholly-owned)[3]

Valorize pioneering technology platforms

SupraAntigen® & Morphomer®

- Clinical development of a-syn[4] and TDP-43[5] PET[6] tracers
- Candidate NLRP3[7] inhibitor IND-ready for clinical development by year end

Strong financial position

Operating capital foundation:

- Partner payments in 2024:
  - **ACI-24.060** (Takeda) $100 million upfront payment
  - **ACI-35.030** (Janssen J&J) CHF25 million milestone payment
- Cash runway into 2027

Cash runway enables achievement of key milestones & execution of value-generating innovation

(1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha-synuclein; (5) TAR DNA-binding protein 43; (6) Positron emission tomography; (7) (NOD)-like receptor protein 3

AC Immune: Pioneering science and precision medicine

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention

9. Agenda items and proposals of the Board of Directors



Agenda item 1

2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report

1.1 Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory Financial Statements

- The Board of Directors (Board) proposes that the 2024 IFRS Consolidated Financial Statements and the 2024 Statutory Financial Statements be approved

Agenda item 1

2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report

1.2 Advisory vote on the 2024 Compensation Report

- The Board proposes that the 2024 Compensation Report be endorsed (non-binding advisory vote)

Agenda item 2

Appropriation of Losses

- The Board proposes the following appropriation of losses:

	In CHF K
Accumulated profit (loss) at Jan 1, 2024	(310,998)
Net profit (loss) for the year 2024	(45,848)
Accumulated losses brought forward	(356,846)

Under IFRS accounting standards, the consolidated net loss for the business year 2024 amounted to CHF 50,916K

Agenda item 3

Discharge of the Members of the Board of Directors and the Executive Committee

- The Board proposes that all Members of the Board and of the Executive Committee (EC) be discharged from their liabilities for their activities in the financial year 2024

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Committee

4.1 Binding vote on maximum aggregate compensation for Members of the Board from the AGM 2025 to the AGM 2026

- The Board proposes the approval of the total maximum amount of compensation for the Members of the Board of CHF 1,029,000 (excluding employer social security contributions) covering the period from the AGM 2025 to the AGM 2026.

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Committee

4.2 Binding vote on maximum aggregate compensation for Members of the Executive Committee for the financial year 2026

- The Board proposes the approval of the total maximum amount of compensation for the Members of the EC of CHF 7,496,000 (excluding employer social security) from 1 January 2026 to 31 December 2026.

Agenda item 5

Re-elections and Elections

5.1 Re-election of Members of the Board of Directors

- The Board proposes that each of the following persons be re-elected as Member of the Board for a term of office until the end of the AGM 2026:
  - Monika Bütler
  - Carl June
  - Andrea Pfeifer
  - Roy Twyman

Agenda item 5

Re-elections and Elections

5.2 Election of Members and the Chair of the Board of Directors

- The Board proposes that each of the following persons be elected for a term of office until the end of the AGM 2026:
  - Renée Aguiar-Lucander as Member of the Board, and
  - Martin Zügel as Member and Chair of the Board

Agenda item 5

Re-elections and Elections

5.3 Re-election of Members of the Compensation, Nomination and Corporate Governance Committee

- The Board proposes that:
  - Monika Bütler, and
  - Roy Twyman

  be re-elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term of office until the end of the AGM 2026

Agenda item 5

Re-elections and Elections

5.4 Election of Member of the Compensation, Nomination and Corporate Governance Committee

- The Board proposes that Martin Zügel be elected as Member of the Compensation, Nomination & Corporate Governance Committee for a term of office until the end of the AGM 2026.

Agenda item 5

Re-elections and Elections

5.5 Re-election of the Statutory Auditors

- The Board proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re-elected as Statutory Auditors for a term of office for the financial year 2025.

Agenda item 5

Re-elections and Elections

5.6 Re-election of the Independent Proxy

- The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re-elected as Independent Proxy for a term of office until the end of the AGM 2026.

Agenda item 6

Changes in the Articles of Association

- The Board of Directors has withdrawn its proposals for agenda items 6.1 and 6.2

We thank you for your attendance and your continued support.